What is ZEO SCIENTIFIX INC's earnings per share (EPS)?

ZEO SCIENTIFIX INC (ZEOX) reported diluted earnings per share of -$0.86 for fiscal year 2025. This represents a -16.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

ZEO SCIENTIFIX INC (ZEOX) Financials

ZEOX

FY2025 annual

Revenue $5.2M +12.5% YoY

Net Income -$5.5M -17.3% YoY

EPS (Diluted) -$0.86 -16.2% YoY

Free Cash Flow -$741K YoY not available

Market Cap $9.0M as of Sep 10, 2026

Price / Sales 1.3x on $7.0M revenue, trailing 12 months to April 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to April 30, 2026

Price / Book 12.7x on $712K equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Apr 30, 2026 Reported Jun 15, 2026 Currency USD FYE October

Newest figures come from the 10-Q for Q2 FY2026, filed Jun 15, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ZEOX SEC filings page.

ZEO SCIENTIFIX INC (ZEOX) reported $5.2M in revenue for fiscal year 2025, up 12.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ZEOX FY2025 2026-08-30

Zeo ScientifiX’s dominant mechanic is high gross margins overwhelmed by fixed operating costs and tight working capital.

Accounting scale has not translated into operating profitability: gross margin was 82.1%, yet operating loss remained -103.6% of sales in FY2025. Operating cash flow improved nearly 50% from FY2024 to -$718K, while free cash flow was -$741K; their near match indicates cash use was primarily operational rather than driven by capital spending.

Overhead remains the central constraint: SG&A was $9.65M against $5.20M of FY2025 revenue, leaving gross profit unable to absorb operating costs. Gross margin fell from 88.9% in FY2023 to 82.1% in FY2025, pointing to a less favorable margin mix or higher direct costs rather than a pure volume story.

Liquidity and solvency are separate pressures: the reported liquidity comparison was 3.7 months, while the current ratio was 0.3x; both point to limited near-term flexibility. Liabilities exceeded assets in FY2025, and financing supplied $305K, making the balance-sheet issue structural rather than simply a one-year cash-flow fluctuation.

Financial Health Signals

Financial health score not available

ZEO SCIENTIFIX INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-70.01

ZEO SCIENTIFIX INC scores -70.01, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($9.0M) relative to total liabilities ($3.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/8

ZEO SCIENTIFIX INC passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

ZEO SCIENTIFIX INC reported a net loss of $5.5M while operations used $718K of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

ZEO SCIENTIFIX INC reported an operating loss of $5.4M against $98K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.6M

YoY+124.6%

QoQ+78.5%

5Y CAGR+16.6%

10Y CAGR+44.1%

ZEO SCIENTIFIX INC generated $2.6M in revenue in Q2 2026. This represents an increase of 124.6% from the same quarter a year earlier. Against the prior quarter it is up 78.5%.

EBITDA

-$493K

YoY+64.2%

QoQ+42.6%

ZEO SCIENTIFIX INC's EBITDA was -$493K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 64.2% from the same quarter a year earlier. Against the prior quarter it is up 42.6%.

Net Income

-$145K

YoY+89.6%

QoQ+83.0%

ZEO SCIENTIFIX INC reported -$145K in net income in Q2 2026. This represents an increase of 89.6% from the same quarter a year earlier. Against the prior quarter it is up 83.0%.

EPS (Diluted)

-$0.02

YoY+90.9%

QoQ+83.3%

ZEO SCIENTIFIX INC earned -$0.02 per diluted share (EPS) in Q2 2026. This represents an increase of 90.9% from the same quarter a year earlier. Against the prior quarter it is up 83.3%.

Cash & Balance Sheet

Free Cash Flow

-$202K

QoQ+58.4%

ZEO SCIENTIFIX INC recorded an outflow of $202K in free cash flow in Q2 2026, representing a cash shortfall after capex. Against the prior quarter it is up 58.4%.

Cash & Debt

$1.8M

YoY+240.6%

QoQ+79.2%

5Y CAGR+56.6%

10Y CAGR+47.4%

ZEO SCIENTIFIX INC held $1.8M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

YoY+21.5%

QoQ+0.8%

5Y CAGR-62.8%

ZEO SCIENTIFIX INC had 8M shares outstanding in Q2 2026. This represents an increase of 21.5% from the same quarter a year earlier. Against the prior quarter it is up 0.8%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

79.6%

YoY+1.9pp

QoQ-0.9pp

5Y change-9.0pp

10Y change-11.9pp

ZEO SCIENTIFIX INC's gross margin was 79.6% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 1.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.9 percentage points.

Operating Margin

-19.8%

QoQ+40.9pp

ZEO SCIENTIFIX INC's operating margin was -19.8% in Q2 2026, reflecting core business profitability. Against the prior quarter it is up 40.9 percentage points. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

-5.6%

QoQ+53.3pp

ZEO SCIENTIFIX INC's net profit margin was -5.6% in Q2 2026, showing the share of revenue converted to profit. Against the prior quarter it is up 53.3 percentage points. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

-20.4%

ZEO SCIENTIFIX INC's ROE was -20.4% in Q2 2026, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

$31K

YoY-26.2%

QoQ+63.2%

ZEO SCIENTIFIX INC invested $31K in research and development in Q2 2026. This represents a decrease of 26.2% from the same quarter a year earlier. Against the prior quarter it is up 63.2%.

Capital Expenditures

$64K

QoQ+357.1%

ZEO SCIENTIFIX INC invested $64K in capex in Q2 2026, funding long-term assets and infrastructure. Against the prior quarter it is up 357.1%.

Share Buybacks

Not reported for Q2 2026.

ZEOX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ZEOX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$7.0M	$5.2M+12.5%	$4.6M+1.4%	$4.6M-29.8%	$6.5M+16.0%	$5.6M+83.2%	$3.1M+79.5%	$1.7M+76.5%	$965K+69.3%	$570K+208.2%	$185K+25.2%	$148K+200.1%	$49K-40.7%	$83K-4.8%	$87K+382.0%	$18K
Cost of Revenue	$1.3M	$931K+10.3%	$844K+66.1%	$508K-32.6%	$754K+37.5%	$548K+37.4%	$399K+32.5%	$301K+43.7%	$209K+30.3%	$161K+70.2%	$94K+91.1%	$49K+146.3%	$20K-54.9%	$44K-27.3%	$61K+455.9%	$11K
Gross Profit	$5.7M	$4.3M+13.0%	$3.8M-6.8%	$4.0M-29.4%	$5.7M+13.6%	$5.0M+90.0%	$2.7M+89.6%	$1.4M+85.6%	$755K+84.6%	$409K+352.3%	$90K-7.9%	$98K+237.1%	$29K-24.4%	$39K+48.0%	$26K+267.4%	$7K
R&D Expenses	N/A	$100K-39.0%	$164K-82.2%	$923K+16.6%	$791K-29.4%	$1.1M+379.6%	$234K+325.7%	$55K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$9.8M	$9.7M+6.1%	$9.1M-15.9%	$10.8M-25.8%	$14.6M-18.1%	$17.8M+17.9%	$15.1M+375.0%	$3.2M-25.1%	$4.2M	N/A	N/A	N/A	$95K+117.5%	$44K+201.4%	$14K+159.9%	$6K
Operating Income	-$4.1M	-$5.4M-1.3%	-$5.3M+21.4%	-$6.8M+23.5%	-$8.8M+30.6%	-$12.7M-2.5%	-$12.4M-600.1%	-$1.8M+49.1%	-$3.5M	N/A	N/A	-$744K	N/A	N/A	N/A	N/A
EBITDA	N/A	-$5.3M-1.3%	-$5.2M+16.5%	-$6.3M+26.2%	-$8.5M+32.9%	-$12.7M-2.3%	-$12.4M-603.9%	-$1.8M+49.4%	-$3.5M	N/A	N/A	-$744K	N/A	N/A	N/A	N/A
Interest Expense	$76K	$98K+6.5%	$92K-78.7%	$431K+8.2%	$398K+949.9%	$38K-78.7%	$178K+281.4%	$47K-79.6%	$228K-60.4%	$576K+4425.2%	$13K	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	$0	$0	$0	$0	$0	$0	N/A	N/A	N/A	N/A	N/A
Net Income	-$3.9M	-$5.5M-17.3%	-$4.7M+32.7%	-$7.0M+21.5%	-$8.9M+30.3%	-$12.8M-1.4%	-$12.6M-624.3%	-$1.7M+49.8%	-$3.5M	N/A	N/A	-$738K-1021.8%	-$66K-104.6%	-$32K-141.3%	-$13K-13.7%	-$12K
EPS (Basic)	N/A	-$0.86-16.2%	-$0.74+25.3%	-$0.99+36.5%	-$1.56	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$0.58	-$0.86-16.2%	-$0.74+25.3%	-$0.99	-$1.56	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	6M+1.2%	6M-9.8%	7M	6M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$2.6M+124.6%	$1.4M+32.7%	$1.7M+33.0%	$1.3M+19.7%	$1.1M+1.6%	$1.1M-5.5%	$1.2M-12.5%	$1.1M-10.6%
Cost of Revenue	$526K+105.5%	$281K+47.1%	$256K+13.8%	$228K+29.5%	$256K-9.9%	$191K+20.1%	$225K+67.9%	$176K+8.6%
Gross Profit	$2.1M+130.1%	$1.2M+29.6%	$1.4M+37.2%	$1.1M+17.8%	$893K+5.4%	$899K-9.6%	$1.0M-20.9%	$915K-13.6%
R&D Expenses	$31K-26.2%	$19K+216.7%	N/A	N/A	$42K+740.0%	$6K-77.8%	$57K+328.6%	$75K-77.6%
SG&A Expenses	$2.6M+12.2%	$2.0M-5.1%	$2.1M-15.5%	$3.1M+51.2%	$2.3M-5.1%	$2.2M-0.2%	$2.4M-3.1%	$2.1M-16.8%
Operating Income	-$512K+63.3%	-$878K+29.9%	-$668K+53.1%	-$2.1M-77.3%	-$1.4M+10.9%	-$1.3M-7.8%	-$1.4M-15.6%	-$1.2M+19.2%
EBITDA	-$493K+64.2%	-$859K+30.4%	-$648K+53.9%	-$2.1M-78.4%	-$1.4M+10.8%	-$1.2M-8.0%	-$1.4M-46.1%	-$1.1M+18.7%
Interest Expense	$11K-47.6%	$10K-54.5%	$32K+45.5%	$23K0.0%	$21K+5.0%	$22K-18.5%	$22K-75.3%	$23K-86.6%
Net Income	-$145K+89.6%	-$852K+31.5%	-$815K+35.0%	-$2.1M-104.7%	-$1.4M+0.6%	-$1.2M-19.5%	-$1.3M-14.9%	-$1.0M+37.5%
EPS (Basic)	-$0.02+90.9%	-$0.12+40.0%	-$0.12+36.8%	-$0.32-100.0%	-$0.22+4.3%	-$0.20-17.6%	-$0.19-26.7%	-$0.16+30.4%
EPS (Diluted)	-$0.02+90.9%	-$0.12+40.0%	-$0.12+36.8%	-$0.32-100.0%	-$0.22+4.3%	-$0.20-17.6%	-$0.19-26.7%	-$0.16
Diluted Shares (Avg)	8M+22.3%	7M+10.7%	N/A	6M+2.3%	6M+2.8%	6M+2.5%	N/A	6M

Not reported in any period shown, so not listed: Income Tax.

ZEOX Balance Sheet

ZEOX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$1.5M-7.1%	$1.6M-40.9%	$2.8M-55.1%	$6.2M+220.8%	$1.9M+44.9%	$1.3M+105.6%	$649K+454.6%	$117K-68.9%	$377K+439.0%	$70K-54.2%	$153K+1295.2%	$11K-66.3%	$32K+75.0%	$19K-10.6%	$21K
Current Assets	$958K-17.8%	$1.2M-47.1%	$2.2M-49.6%	$4.4M+744.2%	$517K-38.9%	$846K+136.3%	$358K+236.9%	$106K-62.2%	$281K+653.7%	$37K-75.3%	$151K+1280.3%	$11K	N/A	N/A	N/A
Cash & Equivalents	$221K-66.4%	$657K-62.6%	$1.8M-53.2%	$3.8M+3356.8%	$109K-81.6%	$591K+345.7%	$133K+208.2%	$43K+8.7%	$40K+50.9%	$26K-30.2%	$38K+15295.5%	$244-98.5%	$16K+584.8%	$2K-80.7%	$12K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$423K+82.3%	$232K-25.2%	$310K+24.7%	$249K+5.8%	$235K+60.0%	$147K+88.3%	$78K	$0-100.0%	$120K+1102.3%	$10K+518.4%	$2K-85.0%	$11K	N/A	N/A	N/A
Accounts Receivable	$35K-82.0%	$194K+977.8%	$18K-67.3%	$55K-47.1%	$104K+254.4%	$29K+12.9%	$26K-45.8%	$48K-55.2%	$107K+9437.3%	$1K-94.3%	$20K	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$3.0M-10.5%	$3.3M-18.1%	$4.0M-6.7%	$4.3M-6.2%	$4.6M+68.7%	$2.7M+23.3%	$2.2M+60.9%	$1.4M-65.0%	$3.9M+361.2%	$853K+510.4%	$140K+121.1%	$63K+198.9%	$21K+13.5%	$19K+148.8%	$7K
Current Liabilities	$2.9M-12.6%	$3.3M-18.0%	$4.0M-1.3%	$4.1M-1.5%	$4.1M+62.5%	$2.5M+23.4%	$2.1M+54.6%	$1.3M-65.7%	$3.9M+355.0%	$853K	N/A	$63K+198.9%	$21K+13.5%	$19K+148.8%	$7K
Non-Current Liabilities	$77K+862.5%	$8K-38.5%	$13K-94.8%	$249K-47.3%	$472K+153.2%	$186K+21.7%	$153K+256.4%	$43K-18.5%	$53K	$0	N/A	$0	$0	$0	$0
Long-Term Debt	N/A	N/A	$68K	N/A	N/A	N/A	$153K	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$1.4M+13.9%	-$1.7M-33.2%	-$1.2M-165.7%	$1.9M+170.9%	-$2.7M-91.5%	-$1.4M+10.9%	-$1.6M-24.2%	-$1.3M+64.6%	-$3.6M-354.2%	-$783K-6194.9%	$13K+124.6%	-$52K-561.1%	$11K+18680.3%	-$61-100.5%	$13K
Retained Earnings	-$67.7M-8.9%	-$62.2M-8.2%	-$57.5M-13.8%	-$50.5M-21.4%	-$41.6M-44.2%	-$28.9M-77.3%	-$16.3M-11.9%	-$14.5M-31.2%	-$11.1M-424.5%	-$2.1M-145.7%	-$860K-604.9%	-$122K-117.0%	-$56K-133.7%	-$24K-105.2%	-$12K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$3.9M+170.8%	$2.6M+65.9%	$1.5M-7.1%	$1.7M-25.6%	$1.4M-25.7%	$1.6M-36.3%	$1.6M-40.9%	$2.2M-9.6%
Current Assets	$3.3M+277.6%	$2.0M+84.1%	$958K-17.8%	$1.1M-38.4%	$865K-39.0%	$1.1M-42.4%	$1.2M-47.1%	$1.7M+60.0%
Cash & Equivalents	$1.8M+240.6%	$1.0M+43.1%	$221K-66.4%	$314K-71.6%	$542K-27.3%	$720K-38.6%	$657K-62.6%	$1.1M+74.6%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$686K+191.9%	$502K+104.9%	$423K+82.3%	$258K+3.2%	$235K-13.6%	$245K-22.5%	$232K-25.2%	$250K-2.9%
Accounts Receivable	$276K+2409.1%	$63K+950.0%	$35K-82.0%	N/A	$11K-81.7%	$6K-92.2%	$194K+977.8%	$19K-8.5%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0-100.0%
Total Liabilities	$3.2M-10.2%	$3.0M-12.0%	$3.0M-10.5%	$4.0M+8.9%	$3.5M-2.7%	$3.4M-14.8%	$3.3M-18.1%	$3.6M+4.8%
Current Liabilities	$3.1M-9.9%	$2.9M-13.8%	$2.9M-12.6%	$3.9M+6.6%	$3.5M-4.6%	$3.3M-14.6%	$3.3M-18.0%	$3.6M+9.6%
Non-Current Liabilities	$63K-23.2%	$68K+1033.3%	$77K+862.5%	$91K+911.1%	$82K+645.5%	$6K-64.7%	$8K-38.5%	$9K-94.4%
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$51K
Total Equity	$712K+133.9%	-$383K+78.8%	-$1.4M+13.9%	-$2.3M-62.7%	-$2.1M-23.5%	-$1.8M-19.7%	-$1.7M-33.2%	-$1.4M-39.1%
Retained Earnings	-$68.7M-6.0%	-$68.6M-8.1%	-$67.7M-8.9%	-$66.9M-9.8%	-$64.8M-8.2%	-$63.5M-8.4%	-$62.2M-8.2%	-$61.0M-8.1%

Not reported in any period shown, so not listed: Goodwill.

ZEOX Cash Flow Statement

ZEOX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$1.2M	-$718K+50.5%	-$1.4M+34.0%	-$2.2M+30.6%	-$3.2M-18.1%	-$2.7M-47.9%	-$1.8M-220.5%	-$565K-10.4%	-$512K+41.9%	-$882K-60.8%	-$548K-22.8%	-$447K-614.3%	-$63K-108.7%	-$30K-242.4%	-$9K+32.3%	-$13K
Depreciation & Amortization	N/A	$73K-1.4%	$74K-84.8%	$486K+46.2%	$333K+530.9%	$53K+43.3%	$37K+148.6%	$15K+88.8%	$8K-59.4%	$19K+5498.6%	$345+301.2%	$86	$0	N/A	N/A	N/A
Stock-Based Compensation	N/A	$4.7M+21.8%	$3.9M+20.1%	$3.2M-18.1%	$3.9M-54.7%	$8.7M-12.7%	$9.9M+1263.0%	$727K-81.9%	$4.0M-30.9%	$5.8M	$0-100.0%	$268K	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	$23K	N/A	$26K-96.8%	$825K+94.2%	$425K+206.2%	$139K+323.7%	$33K+616.5%	$5K-89.9%	$45K+71.5%	$26K+1426.3%	$2K	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	-$741K	N/A	-$2.2M+44.3%	-$4.0M-28.5%	-$3.1M-59.1%	-$2.0M-226.2%	-$598K-15.8%	-$517K+44.3%	-$927K-61.3%	-$575K-28.2%	-$448K	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	-$23K+48.9%	-$45K-107.3%	$615K+174.6%	-$825K-94.2%	-$425K-206.2%	-$139K-323.7%	-$33K-134.3%	$95K+311.5%	-$45K-124.2%	-$20K-154.7%	-$8K	N/A	N/A	N/A	N/A
Financing Cash Flow	$2.3M	$305K-23.0%	$396K+195.4%	-$415K-105.4%	$7.6M+191.1%	$2.6M+8.9%	$2.4M+250.3%	$688K+63.7%	$420K-55.3%	$940K+68.8%	$557K+13.3%	$492K+950.5%	$47K+11.5%	$42K	$0-100.0%	$25K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$138K+3.5%	-$471K-824.6%	-$383K-4.6%	-$257K-173.4%	-$143K+65.5%	$65K+111.3%	-$366K-265.6%	-$94K+79.7%
Depreciation & Amortization	$19K+18.8%	$19K+5.6%	$20K+11.1%	$19K+5.6%	$16K-15.8%	$18K-5.3%	$18K+12.5%	$18K-41.9%
Stock-Based Compensation	$590K-46.2%	$592K-45.7%	N/A	N/A	$1.1M	$1.1M+41.1%	N/A	N/A
Capital Expenditures	$64K	$14K	$0	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	-$202K	-$485K	-$383K	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$312K	-$14K	$0	N/A	N/A	N/A	$0-100.0%	N/A
Financing Cash Flow	$642K+1934.3%	$1.3M+64800.0%	$290K+453.7%	$52K-89.6%	-$35K-218.2%	-$2K+77.8%	-$82K-149.1%	$498K+1760.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

ZEOX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ZEOX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	82.1%+0.4pp	81.7%-7.1pp	88.8%+0.5pp	88.4%-1.8pp	90.2%+3.2pp	87.0%+4.6pp	82.3%+4.0pp	78.3%+6.5pp	71.8%+22.9pp	48.9%-17.6pp	66.5%+7.3pp	59.2%+12.8pp	46.4%+16.6pp	29.9%-9.3pp	39.2%
Operating Margin	-103.6%	-115.1%	-148.5%	-136.2%	-227.7%	-407.0%	-104.4%	-361.9%	N/A	N/A	-504.2%	N/A	N/A	N/A	N/A
Net Margin	-106.2%	-101.8%	-153.3%	-137.1%	-227.9%	-411.8%	-102.1%	-358.9%	N/A	N/A	-500.1%	-133.8%	-38.8%-23.5pp	-15.3%+49.5pp	-64.8%
Return on Equity	N/A	N/A	N/A	-471.0%	N/A	N/A	N/A	N/A	N/A	N/A	-5746.8%	N/A	-283.9%	N/A	-88.3%
Return on Assets	-361.6%-75.2pp	-286.4%-35.2pp	-251.1%-107.7pp	-143.5%+516.5pp	-660.0%+283.2pp	-943.1%-675.5pp	-267.7%+2690.4pp	-2958.1%	N/A	N/A	-483.9%+117.9pp	-601.8%-502.7pp	-99.1%-27.2pp	-71.8%-15.4pp	-56.5%
Current Ratio	0.330.0x	0.35-0.2x	0.55-0.5x	1.07+0.9x	0.13-0.2x	0.33+0.2x	0.17+0.1x	0.080.0x	0.070.0x	0.04	N/A	0.17	N/A	N/A	N/A
Debt-to-Equity	N/A	N/A	N/A	2.28	N/A	N/A	N/A	N/A	N/A	N/A	10.88	N/A	1.87	N/A	0.56
Asset Turnover	3.40+0.6x	2.81+1.2x	1.64+0.6x	1.05-1.8x	2.90+0.6x	2.29-0.3x	2.62-5.6x	8.24+6.7x	1.51-1.1x	2.65+1.7x	0.97-3.5x	4.50+1.9x	2.55-2.1x	4.69+3.8x	0.87
FCF Margin	-14.2%	N/A	-48.8%+12.7pp	-61.5%-6.0pp	-55.5%+8.4pp	-63.8%-28.7pp	-35.1%+18.4pp	-53.6%	-162.6%	-310.7%	-303.6%	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	79.6%+1.9pp	80.6%-1.9pp	84.5%+2.6pp	82.5%-1.3pp	77.7%+2.8pp	82.5%-3.7pp	81.9%-8.7pp	83.9%-2.9pp
Operating Margin	-19.8%	-60.7%	-40.4%	-158.6%	-121.3%	-115.0%	-114.5%	-107.1%
Net Margin	-5.6%	-58.9%	-49.3%	-158.7%	-121.1%	-114.0%	-100.8%	-92.8%
Return on Equity	-20.4%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-3.7%+93.2pp	-33.1%+47.0pp	-53.4%+23.0pp	-125.4%-79.8pp	-96.9%-24.5pp	-80.2%-37.4pp	-76.3%-37.1pp	-45.6%+20.3pp
Current Ratio	1.05+0.8x	0.70+0.4x	0.330.0x	0.27-0.2x	0.25-0.1x	0.33-0.2x	0.35-0.2x	0.47+0.1x
Debt-to-Equity	4.46	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Asset Turnover	0.66-0.1x	0.56-0.1x	1.08+0.3x	0.79+0.3x	0.80+0.2x	0.70+0.2x	0.76+0.2x	0.490.0x
FCF Margin	-7.8%	-33.5%	-23.2%	N/A	N/A	N/A	N/A	N/A

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Note: Shareholder equity is negative (-$1.4M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.33), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
ZEO SCIENTIFIX INC ZEOX	FY2025	$5.2M	-$5.5M	N/A	$9.0M	—
BETTERLIFE PHARMA INC BETRF	FY2018	N/A	-$121K	N/A	$38.1M	—

Where ZEO SCIENTIFIX INC Ranks

Frequently Asked Questions

What is ZEO SCIENTIFIX INC's annual revenue?

ZEO SCIENTIFIX INC (ZEOX) reported $5.2M in total revenue for fiscal year 2025. This represents a 12.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is ZEO SCIENTIFIX INC's revenue growing?

ZEO SCIENTIFIX INC (ZEOX) revenue grew by 12.5% year-over-year, from $4.6M to $5.2M in fiscal year 2025.

Is ZEO SCIENTIFIX INC profitable?

No, ZEO SCIENTIFIX INC (ZEOX) reported a net income of -$5.5M in fiscal year 2025.

What is ZEO SCIENTIFIX INC's EBITDA?

ZEO SCIENTIFIX INC (ZEOX) had EBITDA of -$5.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is ZEO SCIENTIFIX INC's gross margin?

ZEO SCIENTIFIX INC (ZEOX) had a gross margin of 82.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is ZEO SCIENTIFIX INC's free cash flow?

ZEO SCIENTIFIX INC (ZEOX) recorded an outflow of $741K in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is ZEO SCIENTIFIX INC's operating cash flow?

ZEO SCIENTIFIX INC (ZEOX) recorded an outflow of $718K in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are ZEO SCIENTIFIX INC's total assets?

ZEO SCIENTIFIX INC (ZEOX) had $1.5M in total assets as of fiscal year 2025, including both current and long-term assets.

What are ZEO SCIENTIFIX INC's capital expenditures?

ZEO SCIENTIFIX INC (ZEOX) invested $23K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does ZEO SCIENTIFIX INC spend on research and development?

ZEO SCIENTIFIX INC (ZEOX) invested $100K in research and development during fiscal year 2025.

How many shares does ZEO SCIENTIFIX INC have outstanding?

ZEO SCIENTIFIX INC (ZEOX) had 8M shares outstanding as of fiscal year 2025.

What is ZEO SCIENTIFIX INC's current ratio?

ZEO SCIENTIFIX INC (ZEOX) had a current ratio of 0.33 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is ZEO SCIENTIFIX INC's return on assets (ROA)?

ZEO SCIENTIFIX INC (ZEOX) had a return on assets of -361.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is ZEO SCIENTIFIX INC's P/E ratio?

ZEO SCIENTIFIX INC (ZEOX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to April 30, 2026). The market capitalization is $9.0M as of Sep 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is ZEO SCIENTIFIX INC's price-to-sales ratio?

ZEO SCIENTIFIX INC (ZEOX) trades at 1.3x sales, its market capitalization divided by revenue of $7.0M revenue, trailing 12 months to April 30, 2026. The market capitalization is $9.0M as of Sep 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does ZEO SCIENTIFIX INC's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, ZEO SCIENTIFIX INC (ZEOX) held $221K in cash, cash equivalents and investments, and reported an operating cash outflow of $718K over that year. Dividing the one by the other, the reported balance equals about 4 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is ZEO SCIENTIFIX INC's debt-to-equity ratio negative or not reported?

ZEO SCIENTIFIX INC (ZEOX) has negative shareholder equity of -$1.4M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is ZEO SCIENTIFIX INC's Altman Z-Score?

ZEO SCIENTIFIX INC (ZEOX) has an Altman Z-Score of -70.01, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is ZEO SCIENTIFIX INC's Piotroski F-Score?

ZEO SCIENTIFIX INC (ZEOX) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are ZEO SCIENTIFIX INC's earnings high quality?

ZEO SCIENTIFIX INC (ZEOX) reported a net loss of $5.5M while operations used $718K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can ZEO SCIENTIFIX INC cover its interest payments?

ZEO SCIENTIFIX INC (ZEOX) reported an operating loss of $5.4M against $98K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.